1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Genedrive Plc

Genedrive Plc

LLSE:GDR
1.08
GBX
0.00
(0.00%)
900.90MMarket Cap
Nov 24Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.42
0.37
0.29
0.23
0.11
0.08
0.03
0.03
0.01
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.1
-0.14
-0.24
-0.44
-0.28
-0.25
-0.11
-0.59
-0.01
-0.04
-0.04
-0.04
-0.01
- -
Free Cash Flow per Basic Share
-0.2
-0.21
-0.32
-0.28
-0.08
-0.11
-0.11
-0.12
-0.07
-0.04
-0.03
-0.02
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.98
0.86
0.71
0.28
0.15
-0.1
-0.06
-0.05
0.04
0.05
0.02
0.01
- -
- -
Tangible Book Value per Share
0.7
0.32
0.18
-0.19
0.02
-0.1
-0.06
-0.05
0.04
0.05
0.02
0.01
- -
- -
Basic Weighted Avg Shares
12
12
13
13
23
24
33
33
75
107
119
192
569
716
Sales/Revenue/Turnover
5
4
4
3
3
2
1
1
1
- -
- -
- -
1
- -
Operating Margin (%)
-30.64
-51.03
-109.1
-175.37
-191.07
-271.62
-462.96
-532.58
-797.96
-11,459.18
-9,498.18
-1,600
-704.19
- -
Depreciation Expense
- -
1
- -
1
3
3
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-3
-6
-6
-6
-4
-19
-1
-5
-5
-7
-5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-23.46
-37.65
-81.69
-191.18
-245.74
-307.89
-378.36
-1,833.71
-100.58
-9,540.82
-9,363.64
-2,131.02
-684.69
- -
Working Capital
7
3
6
3
6
3
6
8
3
5
2
5
1
- -
LT Debt
- -
- -
4
5
5
6
8
2
- -
- -
- -
- -
- -
1
Total Equity
12
11
10
4
3
-2
-2
-3
4
6
2
5
1
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-11.12
-14.77
-29.64
-88.96
-178.93
- -
- -
- -
- -
-101.6
-134.61
-191.22
-153.92
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
549
632
1,042
Market Capitalization
13
9
9

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
4
3
2
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
1
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-32.88%
-25.1%
-73.17%
Free Cash Flow
6.79%
8.66%
36.08%
Net Income, GAAP
99.37%
100.32%
-26.06%
Sales/Revenue/Turnover
42%
103.6%
130.12%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gino Miele
Full Time Employees
43
Sector
Health technology
Industry
Medical specialties
Address
The CTF Building Manchester GM United Kingdom M13 9XX
IPO Date
Apr 4, 2007
Website
genedrive.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Genedrive plc (GDR.L) develops and commercializes rapid point-of-need pharmacogenetic testing platforms for personalized medicine in emergency healthcare settings. The company offers the Genedrive System, a semi-automated thermocycler and signal detection platform enabling PCR and isothermal amplification for qualitative in vitro molecular diagnostics; the Genedrive MT-RNR1 ID Kit, a temperature-stable single-use cartridge for detecting genetic risk of antibiotic-induced hearing loss in neonates; and the Genedrive CYP2C19 ID Kit, a point-of-care test for rapid genotyping to guide antiplatelet therapy in cardiovascular emergencies. These products, developed in collaboration with NHS partners, support applications in patient stratification, pathogen detection, and genotyping without requiring cold chain logistics or specialized laboratory infrastructure. Founded in 2007 and headquartered at The Incubator Building, Grafton Street, Manchester, M13 9XX, United Kingdom, Genedrive plc operates primarily in the biotechnology sector with a focus on pharmacogenomics and molecular diagnostics. The company targets healthcare providers in emergency care pathways such as stroke, cardiology, sepsis, and neonatal treatment, with geographic operations centered in the United Kingdom, Europe, and the Middle East. It previously traded as Epistem Holdings plc until a 2016 name change and divested non-core research services in 2018 to concentrate on point-of-care diagnostics. In recent developments, Genedrive completed a placing of 1.60 billion shares at 0.20 pence in November 2025, raising approximately £3.2 million to fund near-term commercialization and market expansion activities. Earlier in 2025, the company raised £1.23 million through a share issuance in April and proposed a share capital reorganization. In 2024, Genedrive secured US regulatory approval for a product, received a NICE recommendation for NHS adoption, and raised £6 million via placing and subscription with retail shareholder participation to advance product deployment.